Human TPO

Human TPO

TPO stands for thrombopoietin, also termed thrombopoiesis stimulating factor (TSF). Human TPO is a recombinant protein optimized for use in cell culture, differentiation studies, and functional assays.

Applications

Human TPO can be used for a variety of applications, including:
  • Megakaryocyte proliferation and differentiation in vitro .
  • In vitro expansion of CD34+ hematopoietic progenitor cells.
  • Differentiation of ES-derived cells towards the hematopoietic lineage.
  • In vitro platelet activation.
  • Apoptosis assays.

Alternative Names

MDGF

Background information

Thrombopoietin (TPO), also known as thrombopoiesis stimulating factor (TSF), is a glycoprotein hormone and the major stimulator of megakaryopoiesis and platelet production. TPO is expressed in liver, kidney, spleen, lung, bone marrow, and brain. The TPO receptor is a product of the proto-oncogene
c-mpl
and displays homology with type I cytokine receptor superfamily members. Analogous to the effect of erythropoietin (EPO), the primary mode of action of TPO is inhibition of apoptosis of its target cells. By contrast, TPO is strongly proapoptotic in the brain and acts as a counterpart of EPO which has neuroprotective properties.

Quality description

Research-grade
cytokines are suitable for a wide variety of cell culture applications. They are sterile-filtered prior to lyophilization. Generally, endotoxin levels are <0.1 ng/μg (<1 EU/μg), and purities are >95%. The biological activity is tested in appropriate bioassays.
Premium-grade
cytokines offer the convenience of high and well-defined biological activities and allow exact unit dosing for demanding applications. The biological activity is determined after lyophilization and reconstitution, and normalized to WHO/NIBSC standards whenever available. In general, endotoxin levels are <0.01 ng/μg (<0.1 EU/μg), and purities are >97%. Lot-specific certificates of analysis are available on request (macstec@miltenyibiotec.de).

Biological activity

  • Proliferation of MO7e cells (NIBSC 03/124)
  • premium grade: ≥ 1×
    10
    7
    U/mg
    (typical activity: ≥ 3×
    10
    7
    U/mg
    )
  • research grade: ≥ 5×
    10
    6
    U/mg
  • Selected references

    1. Laurenti, E. et al. (2015) CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16(3): 302-313
    2. Brault, J. et al. (2014)
      Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
      ex vivo
      models of X
      0
      -linked, AR22
      0
      - and AR47
      0
      - chronic granulomatous diseases.
      Biores Open Access 3(6): 311-326
    3. Steinleitner, K. et al. (2012) EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. Anticancer Res. 32(11): 4883-4889
Product options: 7
130-094-011

Human TPO, research grade

E. coli
10 µg
EUR 155,00 
130-095-745

Human TPO, research grade

E. coli
25 µg
EUR 290,00 
130-094-013

Human TPO, research grade

E. coli
100 µg
EUR 740,00 
130-095-747

Human TPO, premium grade

E. coli
10 µg
EUR 190,00 
130-095-750

Human TPO, premium grade

E. coli
25 µg
EUR 365,00 
130-095-752

Human TPO, premium grade

E. coli
100 µg
EUR 840,00 
130-095-754

Human TPO, premium grade

E. coli
1000 µg
EUR 3.280,00